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Pattern recognition underpins innate immunity; the accurate identiﬁcation of danger,
including infection, injury, or tumor, is key to an appropriately targeted immune response.
Pathogen detection is increasingly well deﬁned mechanistically, but the discrimination of
endogenous inﬂammatory triggers remains unclear. Tenascin-C, a matrix protein induced
upon tissue damage and expressed by tumors, activates toll-like receptor 4 (TLR4)-mediated
sterile inﬂammation. Here we map three sites within tenascin-C that directly and coopera-
tively interact with TLR4. We also identify a conserved inﬂammatory epitope in related
proteins from diverse families, and demonstrate that its presence targets molecules for TLR
detection, while its absence enables escape of innate immune surveillance. These data reveal
a unique molecular code that deﬁnes endogenous proteins as inﬂammatory stimuli by
marking them for recognition by TLRs.
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Detailed insights into the molecular basis of pathogendetection by pattern recognition receptors (PRRs) haverevealed how the toll-like receptor (TLR) family sense
ligands including bacterial lipopolysaccharide (LPS), fungal gly-
cans, protozoan DNA, and viral RNA (reviewed in refs. 1–3), as
well as the way in which nod-like receptors recognize bacterial
invasion4, 5 and rice pathogens6. These data demonstrate how a
speciﬁc immune response to distinct microbial threat is mediated,
enabling rational drug design to combat infectious disease.
However, immunity has evolved to protect us from threat beyond
pathogen invasion, and additional inﬂammatory triggers exist.
Endogenous molecules speciﬁcally expressed, released, or secreted
upon tissue injury are detected by the same PRRs that sense
pathogenic ligands. These damage-associated ligands mediate
tissue repair upon sterile injury but also contribute signiﬁcantly to
chronic inﬂammation associated with autoimmune, ﬁbrotic, and
metabolic diseases, and many are associated with tumorigenesis
(reviewed in refs. 7, 8). The identiﬁcation of endogenous triggers
of inﬂammation raises the question of how PRRs detect this
speciﬁc subset of molecules, while the majority of our self remains
immunologically silent.
TLR4 is a relatively promiscuous immune sensor that recog-
nizes both microbial and endogenous ligands, as well as allergens.
Activation of TLR4 by pathogenic stimuli has been extensively
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Fig. 1 The FBG domains of tenascin-C, -R, and -W can induce NF-kB activation and cytokine synthesis, and bind to TLR4. a Tenascin-C, -R, -W, and -X each
contain an assembly domain, a variable number of epidermal growth factor (EGF)-like repeats, a variable number of ﬁbronectin type III-like repeats (these
can be constitutively expressed (white rectangles) or alternatively spliced (gray rectangles) and a C-terminal ﬁbrinogen-like globe (FBG) domain. The FBG
domains exhibit a similar molecular weight, comprising between 229 and 240 amino acids each (FBG-C: 26.1 kDa, amino acids 1974–2201, FBG-R: 27.0
kDa, amino acids 1128–1359, FBG-W: 27.5 kDa, amino acids 1060–1300, FBG-X: 26.1 kDa, amino acids 4013–4243); protein accession numbers: tenascin-C
(P24821), tenascin-R (Q92752), tenascin-W (Q9UQP3), tenascin-X (P22105). b THP1 NF-kB cells were stimulated with different concentrations of FBG-C,
-R, -W, and -X, or were left unstimulated (−) for 24 h and NF-kB activation measured using QUANTI-Blue. Data are shown as mean± SEM from three
independent experiments. One-way ANOVA vs. non-stimulated, **p< 0.01, ***p< 0.001. c–e Primary human macrophages were stimulated with different
concentrations of FBG-C,-R, -W, and -X, or were left unstimulated (−) for 24 h, and TNF (c), IL-6 (d), and IL-8 (e) levels measured by ELISA. Data are
shown as mean± SEM from three independent donors. One-way ANOVA vs. non-stimulated, *p< 0.05, **p< 0.01, ***p< 0.001. f 96-well plates were
coated with 1 µg ml−1 of FBG-C, -R, -W, or -X, or PBS, and incubated with increasing doses of TLR4. Curves were ﬁtted in GraphPad Prism using one-binding
site hyperbola equation. Data in the graph are shown as mean± SEM from four independent experiments
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01718-7
2 NATURE COMMUNICATIONS |8:  1595 |DOI: 10.1038/s41467-017-01718-7 |www.nature.com/naturecommunications
studied9–11, and details of its activation by the metal allergen
nickel12 and the house dust mite allergen Der p213 are
emerging. However, it is not clear how TLR4 detects endogenous
inﬂammatory stimuli; no structural data are available, and
it is poorly understood on the molecular level what, speciﬁcally,
about these agonists enables their recognition by TLR4, while
other molecules escape the attention of this PRR. Tenascin-C is
an extracellular matrix protein that exhibits a restricted pattern
of expression in healthy tissues, but which is speciﬁcally
upregulated at sites of tissue injury14, where it triggers
inﬂammation by activating TLR4 in cells including macrophages,
dendritic cells, neutrophils, chondrocytes, and synovial
ﬁbroblasts15–17. Tenascin-C has been implicated as one of the
major driving factors of chronic inﬂammation in diseases
including rheumatoid arthritis15, 18, asthma19, tumors20, and
ﬁbrosis21. However, lack of information about the mode of TLR4
activation by tenascin-C has prevented the design of speciﬁc,
effective antagonists.
Here we investigate how tenascin-C is detected by TLR4.
Our data pinpoint three speciﬁc sites within this large,
multi-domain matrix molecule that work together to interact with
and activate TLR4. We also demonstrate that this inﬂammatory
epitope exists in other molecules from distinct protein
families that contain homologous domains, where it deﬁnes
TLR4 recognition. Together these data begin to unravel
the molecular basis of endogenously driven immunity, revealing
a common code that earmarks “dangerous” proteins for
detection by innate immune sensors, and which provides a
tractable target for speciﬁcally reducing pathological “sterile”
inﬂammation.
Results
Analysis of TLR activation by tenascin family members. The
tenascin family comprises four members: tenascin-C, -R, -W, and
-X. Each has a distinct pattern of expression in adults: tenascin-R
is predominantly expressed in the central nervous system (CNS),
tenascin-W in stem cell niches, and tenascin-X in loose con-
nective tissue. Tenascin-C is unique in that it is not constitutively
expressed in most adult tissues but is induced at sites of
inﬂammation14. Each tenascin has a similar domain organization
(Fig. 1a); all are capped by a C-terminal ﬁbrinogen-like globe
(FBG) domain that exhibit a high degree of homology (50–60%
sequence identity) (Supplementary Table 1). We previously
demonstrated that the FBG domain of tenascin-C (FBG-C)
activates TLR4 to drive inﬂammatory cytokine synthesis
in vitro and in vivo15, however, it is not known if the FBG
domains of the other tenascin family members can induce an
immune response.
The FBG domains of tenascin-R, -W, and -X (FBG-R, -W, and
-X) were cloned, expressed, and puriﬁed as described for FBG-C15
(Supplementary Fig. 1). FBG-R and FBG-W induced NF-kB
activation in the human monocytic THP1 cell line, as well as
IL-6, IL-8, and TNF synthesis in primary human macrophages,
to an extent similar to FBG-C. However, FBG-X induced little
NF-kB activation and low levels of cytokines (Fig. 1b–e).
The activities of FBG-R and -W were TLR4 dependent;
being inhibited by a neutralizing TLR4 antibody or by the
TLR4 antagonist TAK 242 (Supplementary Fig. 2a–d). To rule
out any contribution of contaminating endotoxin in
FBG-activated cells, LPS was quantiﬁed in FBG preps and levels
found to be below the threshold of macrophage detection15.
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Fig. 2 Peptide mapping reveals speciﬁc regions in FBG-C involved in TLR4 activation and binding. a Nine peptides of ~30 amino acids long from FBG-C were
synthesized; overlapping amino acid sequences are shown in bold. b THP1 NF-kB cells were stimulated with LPS (0.5 ng ml−1), FBG-C (0.5 µM), or 20, 50,
or 100 µM of peptides 1–9 for 24 h and NF-kB activation was measured using QUANTI-Blue™. Data shown as mean± SEM, n= 4 independent
experiments. One-way ANOVA vs. unstimulated cells. **p< 0.01, ***p< 0.001. c Increasing doses of TLR4 were pre-incubated with 200 µM of peptides
before adding them to 96-well plates coated with 1 µg ml−1 of FBG-C. Curves were ﬁtted in GraphPad Prism using one-binding site hyperbola equation. Data
are shown as mean± SEM, n= 3. d THP1 NF-kB cells were left unstimulated (−) or pre-incubated with 100 µM peptides prior to stimulation with 0.5 µM of
FBG-C for 24 h. NF-kB activation was measured using QUANTI-Blue™. Data shown as mean± SEM, n= 3 independent experiments. Paired t-test vs. FBG-
C only, *p< 0.05, **p< 0.01, ***p< 0.001
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In addition, FBG domains were pre-treated with polymyxin
B before cell stimulation, which inhibits LPS activity but not
that of FBG domains (Supplementary Fig. 2e, f). Moreover,
solid phase binding assays demonstrated that FBG-C, -R,
and -W bound directly to the TLR4 extracellular domain with
similar afﬁnities (KD ~50–60 nM), but that FBG-X was unable to
bind (Fig. 1f), corroborating the activity observed in cellular
assays.
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Three sites in tenascin FBG domains implicated in TLR4
activation. Nine overlapping peptides encompassing the
sequence of FBG-C (Fig. 2a and Supplementary Table 2) were
used to further map the activity of this domain. Only peptides 5
and 6 induced NF-kB activation in THP1 cells (Fig. 2b) and
cytokine synthesis in primary human macrophages, in a TLR4-
dependent manner (Supplementary Fig. 3a, b). Scrambled pep-
tides 5 and 6 were not active, and the activity of peptides 5 and 6
was not affected by polymixin B treatment (Supplementary
Fig. 3c, d). Pre-incubation of TLR4 with peptides 5, 6, or 7 sig-
niﬁcantly reduced receptor binding to FBG-C (Fig. 2c, Supple-
mentary Fig. 3e, and Supplementary Table 3). Moreover, peptide
7 reduced FBG-C-mediated NF-kB activation in THP1 cell lines
by 57% (p= 0.06), while the addition of peptide 5 or 6 with FBG-
C had an additive effect on NF-kB activation (Fig. 2d). Together,
these data highlight areas within FBG-C that can activate TLR4,
as well as areas that contribute to TLR4 binding.
Sequence alignment of tenascin FBG domains conﬁrms a high
degree of conservation (Fig. 3a), and homology models predict
that each exhibits similar subdomain organization and folding
(Supplementary Fig. 4a–c). The amino acids comprising peptides
5 and 6 correspond to loop 5 of FBG-C, which protrudes from the
surface of subdomain P. The overlapping sequence of peptides 5
and 6 (a series of positively charged residues “KTYRK”), create a
cationic ridge containing the sequence KTRYKLK that is present
in FBG-C, -R, and -W, but absent from FBG-X (Fig. 3a, purple
box, Fig. 3b, and Supplementary Fig. 4a). The amino acids
comprising peptide 7 correspond to loop 7, a connecting α-helix
and loop 8, also located in the P subdomain. This region is
conserved in FBG-C, -R, and -W and in the inactive FBG-X, with
the exception of three distinct polar and hydrophobic residues in
loop 7 that are absent in FBG-X (Fig. 3a; black box, Fig. 3b, and
Supplementary Fig. 4a). Finally, a cluster of positively charged
amino acids was observed in the C-terminal loop 10 of FBG-C,
-R, and -W that was notably lacking in FBG-X, whose sequence is
truncated (Fig. 3a; gray box, Fig. 3b, and Supplementary Fig. 4a).
Deﬁning the contribution of loops 5, 7, and 10 to TLR4 acti-
vation. Peptides were synthesized with alanines substituted for
the positively charged residues in loop 5 of FBG-C, and the same
mutations were introduced into the FBG-C protein. Peptide and
protein variants lacking either the ﬁrst 2 (mutant 1) or the last
two (mutant 2) of the positive residues in the KTRYKLK
sequence induced signiﬁcantly less NF-κB activation and cytokine
synthesis compared to wild type, while variants lacking all four
charges (mutant 3) exhibited negligible activity (Fig. 4a and
Supplementary Fig. 5a, b). The afﬁnity of FBG-C binding to TLR4
was slightly reduced upon loss of two positive charges and a
larger, though still modest, reduction was observed upon loss of
all four positive charges (Fig. 4a and Supplementary Table 4a). To
deﬁne the minimum sequence of loop 5 required for TLR4 acti-
vation, a panel of peptides was synthesized, ranging from the 5
residue KTYRK sequence alone up to the entire 30 residue loop
5 sequence, in addition to a loop 5 peptide from which KTYRK
was deleted (Supplementary Table 2). The two shortest peptides
did not induce NF-kB activation, or cytokine synthesis; longer
variants were active, however deletion of KTYRK rendered these
peptides inactive (Supplementary Fig. 5c). Together, these data
indicate that a minimum of three positively charged amino acids
in loop 5 are essential for TLR4 activation and that optimal
binding to TLR4 requires additional residues outside of loop 5.
To determine whether positive charges in the C-terminal loop
10 of FBG-C contribute to TLR4 activation, two further mutant
proteins were synthesized. FBG-C mutant 4 is truncated at
residue 223 such that this protein lacks the C-terminal “RRKRA”
sequence, while mutant 5 lacks both the C-terminal RRKRA and
the four positive charges in loop 5. Mutant 4 exhibited a modest
decrease in NF-kB activation and cytokine synthesis, while
mutant 5 was not active in these assays, as expected due to the
loss of a positively charged loop 5 (Fig. 4b). Mutant 4 exhibited a
slight reduction in binding to TLR4, however mutant 5 showed a
signiﬁcant reduction in the afﬁnity for TLR4, which was greater
than that observed for FBG-C mutant 3, which lacks only the
positively charged loop 5 (Fig. 4b and Supplementary Table 4b).
These data suggest that loss of the C-terminal charges alone does
not signiﬁcantly impact the ability of FBG-C to bind to and
activate TLR4 but that this region works together with loop 5 to
effectively bind to TLR4.
Finally, to determine the contribution of the polar and
hydrophobic residues present in loop 7 of FBG-C, FBG-C mutant
6 was created in which three amino acids were substituted for
those in FBG-X: D157P, I160L, and N162S. FBG-C mutant 7
contained these three substitutions plus mutation of the four
positively charged amino acids in loop 5. Mutant 6 exhibited a
modest decrease in NF-kB activation and cytokine synthesis,
while mutant 7 was not active in these assays, as expected due to
the loss of positive charge in loop 5 (Fig. 4c). FBG-C mutant 6
also exhibited a modest reduction in binding to TLR4, while
mutant 7 showed a more signiﬁcant reduction in the afﬁnity to
TLR4, similar to FBG-C mutant 3 (Fig. 4c and Supplementary
Table 4c). These data suggest that loop 7 contributes to FBG-C
binding to TLR4, and that cooperation between loops 5 and 7
mediates high-afﬁnity binding to this receptor.
Creating an active FBG-X. To conﬁrm if amino acids identiﬁed
in FBG-C are sufﬁcient to create an FBG domain capable of
binding to and activating TLR4, we generated variants of the
inactive FBG-X in which sequences from loops 5, 7, and 10 of
FBG-C were substituted into the corresponding region of FBG-X.
FBG-X mutant 1 has three amino acids changed to create a
positively charged “KAKYR” sequence in loop 5 analogous to the
KTRYK sequence in FBG-C, FBG-X mutant 2 has the complete
sequence of FBG-C loop 5 inserted, FBG-X mutant 3 includes the
mutations made in FBG-X mutant 2 plus addition of the posi-
tively charged amino acids at the C terminus, and FBG-X mutant
4 includes mutations in loop 5 and the C terminus, plus the three
amino acids substitution in loop 7: P161D, L165I, and S167N
(Fig. 5a). Similarly to wild-type FBG-X, FBG-X mutant 1 was
Fig. 3 Sequence alignment and homology models of the tenascin family FBG domains. a Multiple alignment analysis of the FBG domain of tenascin family
members highlighting the secondary structure of the predicted protein models. Blue line indicates the A-subdomain, red line indicates the B-subdomain,
and yellow line indicates the P-subdomain. The alignment was colored according to the Clustal color scheme. Light blue: hydrophobic, red: positive
charged, green: polar, pink: conserved column of cysteine, violet: negative charged, orange: glycine, yellow: proline, cyan: aromatics. The overlapping
sequence of peptides 5 and 6, the sequence of peptide 7, and the C terminus are indicated with purple, black, and gray boxes, respectively. b Homology
models of the FBG domain of tenascin-C, -R, -W, and -X highlighting the amino acid composition in loop 5, loop 7, and loop 10. The sequence of loop 5 is
depicted in pale orange, within which positively charged residues are colored red, any positive residues in the C-terminal loop 10 are also colored red. The
sequence of loop 7 is colored pale green within which the triad of polar and hydrophobic residues conserved in FBG-C, -R, and -W but absent in FBG-X, are
colored purple, dark green, and blue
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unable to activate NF-kB and induce cytokine synthesis, and did
not bind to TLR4, while FBG-X mutant 2 exhibited a modest
increase in activity at high doses and a low afﬁnity for TLR4
(Fig. 5b, c, d and Supplementary Table 5). These data indicate
that while the positive charges in the KTRYK sequence are
essential for TLR4 activation they are not sufﬁcient, and that
adjacent amino acids in this loop are also required. These data
also conﬁrm that additional sites outside loop 5 are required to
activate and bind to TLR4 effectively. Both FBG-X mutant 3 and
mutant 4 activated NF-kB and induced cytokine synthesis at
similar levels to FBG-C. However, mutant 3 bound to TLR4 with
a low afﬁnity similar to mutant 2, while mutant 4 bound TLR4
with a high afﬁnity comparable to FBG-C (Fig. 5b–d and Sup-
plementary Table 5). These results conﬁrm that loop 7 and the C
terminus of FBG-C can assist loop 5 in binding to TLR4, and
highlight speciﬁc amino acids that contribute to effective receptor
activation. Together, these data demonstrate the cooperative
action of three distinct regions in tenascin FBG domains that
work together to activate TLR4.
Identiﬁcation of related TLR4 agonists. Tenascins are not the
only proteins that contain an FBG domain. First described in
ﬁbrinogen, ﬁbrinogen-related proteins (FRePs) are deﬁned by
their possession of this domain. Twenty-four human FRePs exist
including ﬁbrinogen chains, tenascins, angiopoietins,
angiopoietin-like proteins, ﬁcolins, ﬁbroleukin, ﬁbrinogen-like
protein 1 (FGL1), ﬁbrinogen C domain containing 1 (FIBCD-1),
and microﬁbrillar-associated protein 4 (MFAP4) (Fig. 6a)22. Each
of the human FBG domains exhibits between ~30–40% sequence
identity with ﬁbrinogen23. However, while the sequences of loops
5, 7, and 10 of FBG-C are extraordinarily well conserved
throughout higher eukaryotes (Supplementary Fig. 6a), there is
little sequence conservation in these loops among other human
a
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Fig. 4 Pinpointing amino acids in loops 5, 7, and 10 of FBG-C that mediate TLR4 binding and activation. Upper panel: Sequences of wild-type FBG-C and
mutants 1–7, highlighting wild-type amino acids in blue and mutations in red (loop 5 variants are shown in a, loop 10 in b, and loop 7 in c). Second panel:
THP1 NF-kB cells were left unstimulated (−) or stimulated for 24 h with LPS (1 ng ml−1), increasing doses (μM) of FBG-C or FBG-C mutants 1–7. NF-kB
activation was measured using QUANTI-Blue™. Data shown as mean± SEM. n= 4 independent experiments. Paired t-test vs. FBG-C, *p< 0.05, **p< 0.01,
***p< 0.001. Third panel: Primary human macrophages were left unstimulated (−) or stimulated for 24 h with LPS (1 ngml−1), increasing doses (μM) of
FBG-C or FBG-C mutants 1–7. Cytokines synthesis was measured by ELISA. Data shown as mean± SEM. n= 4 independent donors. Paired t-test vs. FBG-C,
*p< 0.05, **p< 0.01, ***p< 0.001. Bottom panel: 96-well plates were coated with 1 µgml−1 of FBG-C or FBG-C mutants 1–7, and TLR4 was added in a
dose-dependent manner. Curves were ﬁtted in GraphPad Prism using one-binding site hyperbola equation. Data shown as mean± SEM; n= 4
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FBG domains (Supplementary Fig. 6b). Comparison of the
structures of each of these domains, or homology models where
crystal structures were not available, demonstrate that each
exhibits the same subdomain organization and folding. This
analysis also revealed that in some FRePs, a non-contiguous series
of positively charged residues derived from loops 5, 6, and 7 come
together to create a cationic ridge analogous to that found on the
surface of FBG-C, -R, and -W, while other FRePs, like FBG-X,
lacked this ridge (Fig. 6b and Table 1). None of the FBG domains
possessed an extended cationic C-terminal akin to loop 10 in the
active tenascins. A number did contain a triad of polar/hydro-
phobic residues in loop 7, although in others these residues were
absent (Table 1). Based on our data from the tenascin family, we
hypothesized that 10 of the other human FBG domains would be
capable of activating TLR4 by virtue of possession of a cationic
ridge containing three or more positively charged residues.
To test this hypothesis, we selected two FBG domains predicted
to activate TLR4; ﬁbrinogen-γ (FIB-G) and ﬁcolin-1 (FIC-1), and
one FBG domain predicted to be incapable of activating TLR4;
angiopoietin-like protein 4 (ALP-4), and we synthesized each as
described for tenascin family domains (Supplementary Fig. 7a–c).
Both FIB-G and FIC-1 induced cytokine synthesis in primary
human macrophages to an extent similar to FBG-C (Fig. 7a–c),
and in a TLR4-dependent manner (Fig. 7d), which was not
inhibited by polymyxin B (Supplementary Fig. 7d). However,
ALP-4 induced no detectable cytokine synthesis (Fig. 7a–d). Solid
phase binding assays conﬁrmed that FIB-G and FIC-1 bound
directly to the extracellular domain of TLR4, though with lower
afﬁnities than FBG-C, and that ALP-4, like FBG-X, was unable to
bind to TLR4 (Fig. 7e). These data support the presence of a
cationic ridge in FBG domains as a determinant of TLR4
activation in vitro. We previously demonstrated that intra-
articular injection of FBG-C in mice provokes synovial
inﬂammation, along with cartilage and bone destruction15. Here
we conﬁrm these data, and show that injecting FBG-C mutant 3
(which lacks all four positive charges in the loop 5 KTRYKLK
sequence, and which was inactive in vitro), did not elicit
inﬂammation or tissue destruction. FIB-G and FIC-1
also stimulated signiﬁcant synovial inﬂammation and tissue
destruction, whereas ALP-4 did not (Fig. 7f, g), demonstrating
that FBG domains possessing a cationic ridge can stimulate
inﬂammation in vivo, whereas FBG domains lacking a cationic
ridge do not.
Discussion
Here we show that TLR4 activation is not restricted to the FBG
domain of tenascin-C and that conserved domains from other
molecules, both within the tenascin family and from diverse
protein families, may also act as inﬂammatory triggers. We
demonstrate that TLR4 activation requires a cationic ridge made
up of non-contiguous positively charged residues derived from
loops 5, 6, and 7 of active FBG domains, and we identify non-
essential roles for hydrophobic/polar residues in loop 7, and
cationic residues in loop 10, that assist with receptor binding.
Finally, our data indicate that this molecular signature creates a
TLR4 activation interface that determines whether an FBG
domain can be detected by this PRR, or whether an FBG domain
will remain immunologically inert (Fig. 8).
In searching for the epitope within tenascin-C that triggers
innate immune responses, we identiﬁed four novel TLR4 agonists
and predict a further 8 likely agonists. Our data are consistent
with studies demonstrating that ﬁbrinogen activates TLR424–30,
but also provide evidence implicating tenascin-W, tenascin-R,
angiopoietins-1 and -2, angiopoietin-like proteins 1, 2, and 6,
ﬁcolin-1, FGL1 and ﬁbroleukin in TLR4 activation.
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Fig. 5Mutations in FBG-X confer TLR4-activating ability. a FBG-X chimeric proteins were designed to introduce the amino acids found in FBG-C to activate and
bind to TLR4 (red) into the FBG-X sequence (blue). b ThP1 NF-kB cells were left unstimulated (−) or stimulated for 24 h with 0.5 ngml−1 of LPS or increasing
doses (μM) of FBG-C, FBG-X, FBG-X mutant 1, 2, 3, and 4. NF-kB activation was measured using QUANTI-Blue™. Data shown as mean± SEM. n= 3
independent experiments. One-way ANOVA vs. FBG-C. c Primary human macrophages were left unstimulated (−) or stimulated for 24 h with 1 ngml−1 of LPS
or increasing doses (μM) of FBG-C, FBG-X, FBG-X mutant 1, 2, 3, and 4. Cytokine synthesis was measured by ELISA. Data shown as mean + SEM. n= 3
independent donors. One-way ANOVA vs. FBG-C. d 96-well plates were coated with 1 µgml−1 of FBG-C, FBG-X, FBG-X mutant 1, 2, 3, and 4, and TLR4 was
added in a dose-dependent manner. Data shown as mean± SEM. n= 4 independent experiments
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Like tenascin-C, tenascin-W exhibits restricted expression in
healthy tissue31, and is responsive to inﬂammatory stimuli32. It is
also upregulated in many solid tumors, where expression levels
are reliable markers of disease detection and prognosis33–35.
Upregulation of TLR4 in tumors is reported to exhibit both anti-
and pro-tumorigenic effects36, which are likely dependent on the
activating stimuli within the tumor microenvironment. Our data
suggest that activation of TLR4 by FBG-W within the tumor
stroma could directly affect tumor cell phenotype, and/or the
behavior of immune cells resident in the tumor microenviron-
ment, to favor pro-tumoral inﬂammatory signaling, providing a
possible molecular explanation for the association between
tenascin-W and poor patient survival. Tenascin-R expression is
limited to the CNS, where it is constitutively expressed in the
perineuronal nets. Tenascin-R is upregulated at sites of inﬂam-
mation after neural injury37–39 and tenascin-R null mice recover
better after spinal cord injury compared to wild-type mice38. In
vitro, the ﬁbronectin type III repeats (FN6–8) and the EGF-like
domain of tenascin-R induce microglial synthesis of chemokine-
induced cytokine 3 and TNFα40, and the FBG domain enhances
microglial adhesion and migration40. Our data indicate that FBG-
R may also contribute to cytokine synthesis following neural
trauma via activation of microglial or astrocytic TLR4. Notably,
TLR4 agonism was not conﬁned within speciﬁc families of FRePs.
For example, the FBG domain of tenascin-X did not activate
TLR4. This tenascin is constitutively expressed in connective
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Fig. 6 A conserved cationic ridge in ﬁbrinogen-related proteins (FRePs). a Simpliﬁed domain organization of human FRePs: each protein contains distinct
N-terminal sequences but all possess a C-terminal FBG domain, including the four tenascin family members (shown in Fig. 1a), α, β, and γ chains of
ﬁbrinogen, the three angiopoietins, seven of the angiopoietin-like proteins (Angio-LPs), the three ﬁcolins, ﬁbroleukin, FIBCD-1, FGL1, and MFAP4. b The
cationic loop 5 ridge present in FBG-C, -R, and -W, but absent in FBG-X, is conserved in a subset of FRePs, which possess a comparable structural epitope
made up of residues from loops 5, 6, and 7. Homology models of the FBG domains of the three FRePs selected for further analysis are shown together with
that of tenascin-C (FBG-C); these include two predicted TLR4 agonists; the ﬁbrinogen γ chain (FIB-G) and ﬁcolin-1 (FIC-1), and one FBG domain predicted
to be incapable of activating TLR4; angiopoietin-like protein 4 (ALP-4). The region created by residues from loops 5, 6, and 7 on the surface of each FBG
domain is shown in pale orange, within which positively charged residues are colored red
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tissues, such as the dermis and glomeruli, where its role in
maintaining tissue architecture, for example, by regulating col-
lagen ﬁbril formation and elastic ﬁber stability, has been best
studied41. Tenascin-X expression is regulated upon tissue injury,
but unlike other family members, which appear in the early
inﬂammatory stages, tenascin-X appears after the resolution of
inﬂammation during tissue rebuilding42. Consistent with these
reports, while FBG-X does not activate TLR4, this domain can
inﬂuence epithelial-to-mesenchymal transition via interaction
with the small latent complex of TGF-β, exposing active TGF-β43,
suggesting that this family member mediates tissue remodeling
during repair, rather than inﬂammation.
Identiﬁcation of ﬁcolin-1 as a TLR4 agonist was at ﬁrst glance
more surprising; this FReP is best known for triggering
complement-mediated inﬂammation following infection, cell death,
or tissue damage44. However, compared to its siblings, ﬁcolins-2
and -3, which we predict would not activate TLR4, ﬁcolin-1 cir-
culates at far lower levels in the serum, and is the poorest activator
of complement44. Instead, it is predominantly expressed by bone
marrow-derived myeloid cells, and is found tethered to sialic acid
on the surface of monocytes, granulocytes, and activated T cells,
where it is incapable of activating complement45. These data raise
the possibility of an alternative, more localized role for ﬁcolin-1 in
activating TLR4 at sites of inﬂammation. Among our putative TLR4
agonists, angiopoietins-1 and -2, and angiopoietin-like proteins 1
and 2 are known to regulate angiogenesis, while angiopoietin-like
protein 6 is linked with lipid metabolism46, 47. Fibroleukin was
initially identiﬁed as a coagulant48, 49; and diverse roles for FGL1
have been reported, most recently in the recognition of defective
spermatozoa50. However, emerging evidence linking angiopoietin-
like protein 2 with chronic inﬂammation in RA, atherosclerosis,
diabetes, and cancer47, and reports of ﬁbroleukin regulating DC
maturation51 and macrophage activation52, support the idea of
immunomodulatory roles for FRePs. While our study offers proof
of principle of a molecular tag for TLR4 recognition; FBG domains
added exogenously to cells can activate TLR4 in vitro, and cause
inﬂammation in vivo, further work is needed to determine if
endogenously expressed FRePs activate TLR4 in situ, and if so, what
the physiological and pathological signiﬁcance of this might be.
The FBG domains of FRePs are deﬁned by a unique structural
fold; the N-terminal subdomain A is followed by a central
5 stranded beta sheet making up subdomain B, which is linked to
the ﬁnal subdomain P. However, the third strand of the beta sheet
in subdomain B derives from residues that appear sequentially at
the end of subdomain P22 (Fig. 3a). This unusual globular
organization is common to all nine of the human FBG domains
crystallized to date (PDB IDs are listed in Supplementary Table 6)
and is predicted to be conserved in our homology models of the
other 15 FBG domains. The cationic ridge that deﬁnes TLR4
recognition is not a linear epitope; it is derived from non-
contiguous residues distant in sequence but brought together in
the protein by the unique fold of this domain, highlighting the
importance of tertiary structure in creating a TLR4 activation
epitope. In full-length FRePs, FBG domains are linked to diverse
N-terminal sequences; and these can include assembly domains.
For example, ﬁcolins form trimers, that further associate into
higher-order polymers53, tenascins exist as trimers (tenascin-R,
-W, and -X) or as hexamers (tenascin-C)54, ﬁbrinogen comprises
a dimer of three non-identical polypeptide chains (α, β, and γ)222,
while angiopoietin-like proteins lack an N-terminal super clus-
tering domain that enables the angiopoietins to oligomerize47.
Our data demonstrate that isolated FBG domains can bind to and
activate TLR4, however it does not provide any information about
FBG behavior in the context of the whole FReP. While multi-
merization does not appear to deﬁne TLR4 agonism per se, this
does not preclude a role for domain oligomerization in TLR4
activation, for example by determining receptor stoichiometry,
binding avidity, and internalization or co-receptor recruitment.
Table 1 Conservation of epitopes involved in TLR4 activation in human FRePs
Protein Cationic ridge Loop 7 Cationic C-terminal Predicted TLR4 activator
Tenascin-C 7 + + Yes
Tenascin-R 7 + + Yes
Tenascin-W 6 + + Yes
Tenascin-X 2 − − No
* Angiopoietin-1 4 − − Yes
* Angiopoietin-2 4 − − Yes
Angiopoietin-4 1 − − No
Angiopoietin-like protein 1 5 + − Yes
Angiopoietin-like protein 2 5 − − Yes
Angiopoietin-like protein 3 0 − − No
Angiopoietin-like protein 4 0 − − No
Angiopoietin-like protein 5 2 − − No
Angiopoietin-like protein 6 5 − − Yes
Angiopoietin-like protein 7 2 − − No
* FIBCD-1 2 − − No
* Fibrinogen α chain 2 − − No
* Fibrinogen β chain 3 + − Yes
* Fibrinogen γ chain 4 − − Yes
Fibrinogen-like protein 1 5 − − Yes
Fibroleukin 5 − − Yes
* Ficolin-1 4 − − Yes
* Ficolin-2 2 − − No
* Ficolin-3 2 − − No
MFAP4 2 + − No
Comparison of the structures (*crystal available) or homology models of the FBG domains from the 24 human FRePs reveals potential new TLR4 agonists. Cationic ridge: the number of positively charged
residues within the region exposed on the surface of the FBG domain around loops 5, 6, and 7. Loop 7: the presence (+) or absence (−) of a triad of polar hydrophobic residues. Cationic C-terminal: the
presence (+) or absence (−) of an extended loop 10 containing a cluster of positive charges. FBG domains were designated potential TLR4 activators if they possessed a cationic ridge comprising 3 or
more positive charges
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Fig. 7 The FBG domains of FIB-G and FIC-1 exhibit pro-inﬂammatory effects in vitro and in vivo. a–c Primary human macrophages were stimulated with
different concentrations of FBG-C, FIB-G, FIC-1, and ALP-4, or were left unstimulated (−) for 24 h. Cytokine levels were measured by ELISA. Data shown as
mean± SEM from at least three independent donors. One-way ANOVA vs. non-stimulated, *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001. d Primary
human macrophages were pre-incubated for 6 h with 3 µM TAK 242 prior to stimulation with FBG-C, FIB-G, FIC-1, and ALP-4 (1 µM), or no stimulation (−)
for 24 h. Cytokine synthesis was measured by ELISA. Data shown as mean± SEM from at least three independent donors. Paired t-test vs. non-treated,
*p< 0.05, **p< 0.01, ***p< 0.001. e 96-well plates were coated with 1 µg ml−1 of FBG-C, FBG-X, FIB-G, FIC-1, and ALP-4, or PBS, and incubated with
increasing doses of TLR4. Curves were ﬁtted in GraphPad Prism using one-binding site hyperbola equation. Data are shown as mean± SEM from three
independent experiments. f, g Synovial inﬂammation was assessed 3 days post injection of each protein (1 µg) or PBS alone into the knees of DBA-1 mice.
The histological score was calculated as the mean of seven sections from each knee joint per mouse. n= 5 mice per group except for FIC-1 (n= 4) (f).
Mann–Whitney non-parametric test vs. PBS, *p< 0.05, **p< 0.01. Images show representative sections stained by haematoxylin and eosin (left panels) or
safranin-O (right panels) (g). Mice injected with FBG-C, FIB-G, and FIC-1 exhibit cell inﬁltration into a thickened synovial lining layer, cellular invasion into
the subchondral bone (arrows indicate bone erosion) and loss of articular cartilage proteoglycan (cp), pathological features not observed in mice injected
with FBG-C mut or ALP-4.Scale bar left panels: 100 μM, right panels: 50 μM
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Biophysical analysis of the mode of TLR4 activation by these
agonists should therefore not solely rely on isolated recombinant
FBG domains, but include intact fully oligomeric proteins.
It is also important to consider what the physiologically rele-
vant presentation of inﬂammatory FBG domains might be.
Constitutive expression of a number of FRePS that contain TLR4-
activating FBG domains raises the related question of how
inﬂammatory activity is regulated. For example, within the
complex insoluble structure of the perineural nets, the FBG
domain of tenascin-R may be physically constrained in a way that
precludes TLR4 binding under normal circumstances. However,
these nets are degraded upon injury, which could release FBG-
containing fragments capable of TLR4 activation. Alternatively,
upregulation of tenascin-R expression upon injury may create
tissue concentrations above the threshold of TLR4 detection, or
soluble de novo tenascin-R may be more readily accessible to cell
surface TLR4. Similar mechanisms may ensure that circulating
ﬁbrinogen does not trigger ectopic systemic inﬂammation; indeed
proteinase-dependent ﬁbrinogenolysis is required to activate
TLR4-mediated anti-fungal immunity29.
Pinpointing sites within FBG-C that are detected by TLR4
highlights a precise target for the amelioration of tenascin-C-driven
chronic inﬂammation; however, the identiﬁcation of a new subset of
protein domains that can activate TLR4 raises more questions than
we originally set out to answer. If we now understand more about
how endogenous molecules can be marked for innate immune
recognition, foremost among the remaining questions must be: why
are there so many different proteins with TLR4-activating FBG
domains? This may represent physiological economy coupled with
intrinsic safeguarding; the fewer endogenous inﬂammatory epitopes
PRRs are alerted by, the smaller the chance of misreading danger
signals. The use of a common “danger domain” within a wide range
of inﬂammatory triggers may also serve to alert the immune
response to danger at different tissue locations, and in response to
different types of threat or cellular stress. Moreover, different FBG
domains may induce distinct inﬂammatory signaling pathways
downstream of TLR4 by virtue of different modes of receptor
activation or co-receptor use. These data reveal an intriguing new
theme underlying the generation of a spectrum of immune
responses in the absence of external pathogens.
Methods
Reagents. All primers were purchased from Invitrogen. Endpoint Chromogenic
LAL Assays and RPMI 1640 were purchased from Lonza, FBS and penicillin/
streptomycin were purchased from Gibco. THP1-Blue™ NF-κB cells, Blasticidin,
Normocin™, QUANTI-Blue™, human polyclonal (pab-hTLR4) and monoclonal
(mabg-hTLR4) TLR4 antibodies, IgG isotype control (pab-sctr) and TAK 242
(CLI-095) TLR4 inhibitor were purchased from InvivoGen. LPS from E. coli,
Serotype EH100 (Ra) (TLR grade™) was purchased from Enzo life sciences. Poly-
myxin B was purchased from Fluka. Tetra-his antibody (346700) was purchased
from Qiagen. M-CSF was purchased from Peprotech. Rabbit F(ab′)2 anti-mouse
IgG-HRP (STAR13B) for use in binding assays, and goat anti-mouse IgG-HRP
(170–6516) for use in western blots were purchased from Bio-Rad. Recombinant
human TLR4 was purchased from R&D systems. This protein was synthesized
using the mouse myeloma NS0-derived cell line, and comprises amino acids Glu24-
Lys631, with a C-terminal Ser and 10-His tag. The purity of recombinant TLR4 was
conﬁrmed by SDS-PAGE and silver staining (Supplementary Fig. 1d).
In-silico analysis of homology and protein modeling. All protein sequences were
obtained from the UniProt Knowledge database and the accession numbers are
presented in Supplementary Tables 7 and 8. Pairwise alignment and multiple
protein alignment analysis were performed using Clustal Omega. Alignments were
colored using Jalview software. Multiple sequence alignments were performed
using Clustal Omega 1.2.1 and colored according to the Clustal color scheme.
Homology models of FBG domains were built using two different methods and
two different templates. The homology modeling functionality of the ICM platform
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Fig. 8 A common danger domain revealed. Three distinct sites within the FBG domain of tenascin-C contribute to TLR4 activation (center panel); a cationic
ridge made up of residues from loops 5–7 (pale orange with positive residues highlighted red), underneath which sits a triad of hydrophobic/polar residues
from loop 7 (green, purple, and blue), plus a C-terminal cationic tail in loop 10 (positive residues highlighted red). The cationic ridge is the dominant
inﬂammatory epitope; its deletion renders inﬂammatory stimuli inert and its ectopic expression can convert immunologically inactive proteins into TLR4
agonists. In addition to tenascin-C, in other proteins that contain FBG domains, possession of this inﬂammatory epitope also confers TLR4-activating
capabilities, irrespective of protein family (*denotes validated domains). Together, these data reveal a common mechanism by which distinct inﬂammatory
triggers, spanning a wide range of tissue locations, induced in response to a spectrum of different threats, can activate TLR4 to raise an immune response
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was used as follows. The sequence of FBG-C was used to query the PDB for
structural homologs using the “PDB Search by Homology” functionality55.
Matches were triaged by their sequence identity, pP values (a predictive measure of
how structurally dissimilar the match is likely to be compared to the query
sequence55 and the resolution of the structure itself). From this analysis, the
structure of ﬁbrinogen-like recognition domain of FIBCD-1 (PDB: 4M7H)56 was
chosen, presenting a sequence identity of 43% and resolution of 2.0 Å. Sequence
alignment of this structure and the tenascin FBG domains was generated using
ICM and optimized by hand. Homology modeling was performed within ICM
using default parameters. Resultant possible models were scored using an energy-
based function and the top 10 superimposed revealing no signiﬁcant structural
difference between them; as such the model with the best score was taken for
further analysis. The majority of the sequence was fully built with reference to the
template; however, the C-terminal ten residues NFRNLEGRRKR extended beyond
the C terminus of the template structures, hence their structure in the model was
not be considered to be predictive. Similarly, SWISSMODEL57 was used to
generate tenascin FBG domain models based on the structure of the C terminus
ﬁbrinogen γ chain (PDB: 1FID)58. Models generated by either method or template
exhibited no signiﬁcant structural difference. Homology models of each of the
other FBG domains were generated using SWISSMODEL. Protein models were
colored and structurally analyzed using Pymol Molecular Graphics System, Version
1.7.4 Schrödinger, LLC and ICM-Pro.
Protein synthesis and biophysical characterization. The FBG domains of
tenascin-R, -W, and -X, and of the ﬁbrinogen γ chain, ﬁcolin-1, and angiopoietin-
like protein 4, were synthesized and puriﬁed as described for the FBG domain of
tenascin-C15. Brieﬂy, the boundaries of the FBG domain of each protein were
determined using alignments published in Uniprot. Each FBG DNA sequence was
ampliﬁed by PCR using primers speciﬁed in Supplementary Tables 9 and 10 and
cDNA clones as templates: tenascin-R (ID: 40114168), tenascin-W (ID: 9020609),
tenascin-X (ID: 5179997) (IMAGE consortium, Source BioScience); ﬁbrinogen
chain γ (ID: 3935073) (MGC Project, GE Healthcare Dharmacon); ﬁcolin-1 (NCBI
RefSeq: NM_002003.2) and angiopoietin-like protein 4 (NCBI RefSeq:
NM_139314.1) (SinoBiological).
Proteins were expressed in E. coli BL21 (DE3) or Rosetta cells and puriﬁed using
two sequential rounds of Ni2 + chromatography (Bio-Rad). Each column was
washed with 100 column volumes of 0.1% Triton-X114 (Sigma-Aldrich, laboratory
grade 9036–19–5, lot no. 072k0049) to remove LPS59, 60, followed by washing with
100 column volumes of binding buffer, before protein elution using 150 mM
imidazole. Proteins were characterized by silver staining and anti-His western blot.
Protein secondary structure was analyzed using the J-815 Circular Dichroism
Spectrometer (Jasco). The CD spectrum was measured in the “far UV” spectral
region (190–250 nm) at 20 °C. Five repeated measurements were taken and the
average plotted and analyzed using Spectra Manager™ II software. The LPS content
in each protein prep used in this study, including the tenascin family FBG domains
(FBG-C, FBG-R, FBG-W, and FBG-X) and the other human FBG domains tested
(FIB-G, FIC-1, and ALP-4) was measured using the Endpoint Chromogenic LAL
Assays (Lonza) according to the manufacturer’s instructions. Each stock solution of
protein was assayed using a protein concentration equivalent to the highest
concentration added in cellular assays. Endotoxin values measured typically fall
between 2 and 9 pg ml−1; if any prep exhibits a value higher than 10 pg ml−1 it is
discarded and not used in any study.
Mutagenesis. Changes in the sequences of FBG domains were made using
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) as
described by the manufacturer. Speciﬁc primers were designed for each mutation as
shown in Supplementary Table 11. Plasmids containing variant PCR products were
sequenced (Euroﬁns, UK) to validate the insertion of the mutations. The clones
with the correct mutant sequences were transformed into BL21 DE3 cells for
protein over-expression and puriﬁcation as described above. Proteins were also
characterized using SDS-PAGE gels, western blots, CD spectroscopy, and the LPS
content was measured.
Peptides. Peptides synthesized by BioGenes; each was provided at a purity of
>90% as a TFA-salt, lyophilized powder. Peptides were reconstituted in sterile PBS
and found to be free from LPS using the Endpoint Chromogenic LAL Assays
(Lonza) as described above.
THP1 NF-kB cell culture and stimulation. THP1-Blue™ NF-κB cells (InvivoGen)
were cultured in RPMI 1640, 10% FBS, 1% penicillin/streptomycin, 10 µg ml−1
blasticidin, and 100 µg ml−1 normocin61. Cells were plated (105 cells per well) in
96-well plates and stimulated with different doses of LPS, recombinant FBG pro-
teins or peptides. As a control for LPS contamination, the different stimuli were
pre-incubated for 30 min with 10 µg ml−1 polymyxin B. In the case of
co-stimulation with peptides, cells were pre-incubated with 100 µM of different
peptides for 30 min at 37 °C and then stimulated with 0.5 µM of FBG-C for 24 h at
37 °C. After 24 h, supernatant was collected and the presence of SEAP was detected
using QUANTI-Blue™ (InvivoGen). Absorbance was read at OD 620 nm on
FluoStar Omega plate reader.
Primary human macrophages culture and stimulation. Human monocytes were
isolated from peripheral blood (London Blood Bank) by ﬁcoll gradient and
counterﬂow centrifugation. Cells were plated (1 million cells per ml) in RPMI 1640,
5% (v/v) FBS, 1% penicillin/streptomycin and differentiated into macrophages for
5 days with 100 ng ml−1 of M-CSF. Macrophages were plated (105 cells per well) in
RPMI 1640, 3% (v/v) FBS and 1% penicillin/streptomycin for 24 h before stimu-
lation with different doses of LPS, recombinant FBG proteins or peptides. As a
control for LPS contamination, the different stimuli were pre-incubated for 30 min
with 10 µg ml−1 polymyxin B (ﬁnal concentration). To assess TLR4 dependency,
cells were pre-incubated with 25 µg ml−1 PAb-hTLR4 antibody or 25 µg ml−1 IgG
isotype control for 1 h at 37 °C, or with 3 µM of TAK 242 TLR4 inhibitor for 6 h at
37 °C prior to cell stimulation with 1 ng ml−1 of LPS, 1 µM of FBG proteins, or 100
µM of peptides. After 24 h, the medium was collected and cytokines levels detected
by ELISA (BD Biosciences) according to the manufacturer’s instructions. Absor-
bance was read at 450 nm on FluoStar Omega plate reader and data analyzed using
Omega software.
Solid phase binding assay. Nunc, Maxisorp 96-well plates (Thermo Scientiﬁc)
were coated with 1 µg ml−1 solution of recombinant FBG protein in PBS and
incubated with shaking overnight at 4 °C. Unspeciﬁc binding was blocked with 10%
BSA in PBST (0.05% tween20) for 2 h at room temperature. TLR4 was added at a
maximum concentration of 27 µg ml−1 followed by a series dilution 1:3 in 2% BSA/
PBST and incubated for 2 h at room temperature. TLR4 binding was detected using
MAb hTLR4 at a ﬁnal concentration of 1 µg ml−1 in 2% BSA/PBST and secondary
antibody anti-mouse IgG-HRP (1:1000 dilution) in PBST. Colorimetric reaction
was started adding TMB substrate (KPL) and incubating for 10 min in the dark.
Color development was stopped using 6% sulfuric acid solution and plates were
read at OD 450 nm in FluoStar Omega plate reader. In the case of blocking TLR4-
FBG-C binding with peptides, TLR4 was pre-incubated with 200 µM of peptides for
1 h at room temperature.
Intra-articular injection of FBG domains. Animals: Eight-week-old male DBA-1
mice were purchased from Charles River and allowed to acclimatize for 7 days. All
animals were fed standard rodent chow and water ad libitum, and were housed
(<six mice per cage) in sawdust-lined cages in an air-conditioned environment
with 12 h light/dark cycles. All animal procedures were approved by the institu-
tional ethics committee and the UK Home Ofﬁce.
FBG injection: Intra-articular injections were carried out as described
previously15. Brieﬂy, mice were anesthetized by inhaled isoﬂuorane. Mice were
then injected with 1 µg FBG in 10 µl of sterile PBS into the right knee joint using a
sterile BD micro-ﬁne 30G insulin syringe. Control mice received an injection of 10
µl PBS alone. At 3 days, mice were killed, and the knee joints were excised and ﬁxed
in 10% (v/v) buffered formalin, decalciﬁed, with 10% EDTA and processed to
parafﬁn.
Histology: Coronal tissue sections (4 µm) were cut at 7 depths throughout the
joint; 80 µm apart and stained with hematoxylin and eosin or Safranin-O to assess
joint pathology. Each joint was scored as described62: 0 = normal; 1 = cell
inﬁltration with no signs of joint erosion; 2 = inﬂammation with the presence of
erosions limited to discrete foci; and 3= severe and extensive joint erosion with
loss of architecture. Histological analysis was performed by investigators blinded to
the experimental groups. The mean score for each animal in an experimental group
was calculated by averaging the histopathologic scores in at least ﬁve section depths
per joint.
Statistics. The data mean± SEM or SD and statistical analysis were calculated
using GraphPad Prism 6 software. Multiple group means were analyzed by one-
way analysis of variance, followed by the Dunnett multiple comparisons test, where
appropriate. Two-tailed, paired t-test was used for experiments involving only two
groups. In vivo data were analyzed by a Mann–Whitney non-parametric test. P
values lower than 0.05 were considered signiﬁcant.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on request.
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